Please assess the completion status of the following clinical trial:

Trial Title: Systematic Search for Primary Immunodeficiency in Adults With Infections

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 yrs old patients~* ≥ 2 bacterial upper or lower respiratory tract infections/years, for at least 2 years, or~* ≥ 1 severe bacterial upper or lower respiratory tract infection requiring hospitalization and IV antibiotics, or~* ≥ 1 invasive infection (meningitis, bacteriemia, arthritis) due to Streptococcus pneumoniae, group A Streptococcus, Haemophilus influenzae, Neisseria meningitidis or Neisseria gonorrhoeae~Exclusion Criteria:~* concomitant, systemic comorbidity that predisposes to infection (solid or hematological cancer, diabetes mellitus, severe alcohol or intravenous drug abuse, chronic liver or kidney failure, human immunodeficiency virus infection, anatomic or functional asplenia, drug-induced 1 neutropenia, or solid organ or hematopoietic stem cell transplantation).~* the presence of a local predisposing factor: cigarette smoking (\> 5 pack-year and/or 5 cigarettes/day), underlying infection (tuberculosis, influenza...), chronic obstructive pulmonary disease, cystic fibrosis or bronchiectasis for pulmonary infections; cerebrospinal leak or preceding upper respiratory tract (URT) infections for non-meningococcal meningitis; oral, dental or skin condition for GAS infections~* use of corticosteroids, non-steroidal anti-inflammatory drugs, immunosuppressants or cytotoxic chemotherapeutics~* PID diagnosed before the infectious episode in question.~* current or recent pregnancy~* hospital-acquired infection (including infections of prostheses).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Patients with bacterial infections (Type: OTHER): Patients with recurrent and/or severe bacterial infections

Based on this trial design, predict the completion outcome and termination type (if applicable).